Sai Parenterals Ltd

Sai Parenterals Earnings Call: Key Takeaways

Sai Parenterals reports Q4 FY26 consolidated revenue of ₹198cr and EBITDA of ₹29cr, following the Noumed acquisition. Standalone FY26 PAT grew 64% YoY.

Sai Parenterals Results Update

Sai Parenterals reported FY26 revenue of ₹380.99 Crore, marking 140.37% growth. Robust performance was driven by CDMO exports and successful integration of its Australian subsidiary.

Value

₹381.0 Cr

Sai Parenterals Fund Raise of ₹285 Cr

Sai Parenterals Limited confirmed zero deviation in utilizing its ₹285 Crore IPO proceeds. The funds were deployed across expansion, R&D, and debt repayment as planned.

Value

₹285.0 Cr

Sai Parenterals Q3 FY26 Results: Net Loss of ₹6.7 Cr

Sai Parenterals Ltd reported revenue from operations of ₹96.2 Cr and a net loss of ₹6.7 Cr for Q3 FY26.

Key figure

Net loss ₹6.7 Cr

Sai Parenterals Financial Results

Sai Parenterals approved audited standalone and consolidated financial results for the year ended March 31, 2026. The board meeting concluded successfully with no other material developments.

Sai Parenterals Board Meeting Date

Sai Parenterals scheduled a board meeting for May 23, 2026. Directors will consider financial results for the quarter and year ended March 2026.

Sai Parenterals Fund Raise of ₹285 Cr

Sai Parenterals Limited filed its quarterly Monitoring Agency Report regarding IPO proceeds. The entire ₹285 Crore fresh issue remains unutilized in an escrow bank account.

Value

₹285.0 Cr